TP53 and neoplasm: The other most notable alteration is biallelic loss-of-function alterations in both RB1 and TP53 in nearly all SCLC tumors, supporting the long-standing concept of loss of tumor suppressor activity as the rate-limiting event for SCLC initiation, which was validated in the genetically engineered mouse models29.